HPV vaccination coverage in the federal state of Belgium according to regions and their impact
Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination covera...
Saved in:
Published in | Facts, views & vision in ObGyn Vol. 10; no. 2; pp. 101 - 105 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Belgium
Universa Press
01.06.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination coverage of more than 80 %. Within 20 to 30 years a reduction in cervical cancer by more than 75 % is expected. Furthermore, there will be a reduction in other HPV related cancers like vaginal, vulva, perineal, anal and oropharyngeal cancers. In order to be successful, a high vaccination coverage is needed. In Belgium, the vaccination was introduced in 2010 in the Flemish community and in 2011 in the French community. In the first vaccinated cohorts the coverage in Flemish and French Communities was respectively 84% (2010) and 29% (2012-2013). The latest data suggest that the Flemish Community (Flanders Region) attained a coverage of 91 % while the French Community (Walloon Region) attained a coverage of around 36 %. The regional difference in coverage offers a real-life case. The worst-case scenario could end up with proportionally one half of country having more HPV related cancers than the other half. Currently efforts are performed to increase the coverage rates in both regions and consequently decreasing this difference. Additionally, the updated recommendations regarding the HPV vaccination by the Belgian NITAG (National Immunization Technical Advisory Group) stated that the HPV vaccination should be gender neutral. This could stimulate the vaccination program and increase the coverage. The coverage rate in Flanders is among the highest in the world and the rate in the French Community is increasing. Efforts should be continued in order to maintain trust and increase the coverage rate. |
---|---|
AbstractList | Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination coverage of more than 80 %. Within 20 to 30 years a reduction in cervical cancer by more than 75 % is expected. Furthermore, there will be a reduction in other HPV related cancers like vaginal, vulva, perineal, anal and oropharyngeal cancers. In order to be successful, a high vaccination coverage is needed. In Belgium, the vaccination was introduced in 2010 in the Flemish community and in 2011 in the French community. In the first vaccinated cohorts the coverage in Flemish and French Communities was respectively 84% (2010) and 29% (2012-2013). The latest data suggest that the Flemish Community (Flanders Region) attained a coverage of 91 % while the French Community (Walloon Region) attained a coverage of around 36 %. The regional difference in coverage offers a real-life case. The worst-case scenario could end up with proportionally one half of country having more HPV related cancers than the other half. Currently efforts are performed to increase the coverage rates in both regions and consequently decreasing this difference. Additionally, the updated recommendations regarding the HPV vaccination by the Belgian NITAG (National Immunization Technical Advisory Group) stated that the HPV vaccination should be gender neutral. This could stimulate the vaccination program and increase the coverage. The coverage rate in Flanders is among the highest in the world and the rate in the French Community is increasing. Efforts should be continued in order to maintain trust and increase the coverage rate. Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination coverage of more than 80 %. Within 20 to 30 years a reduction in cervical cancer by more than 75 % is expected. Furthermore, there will be a reduction in other HPV related cancers like vaginal, vulva, perineal, anal and oropharyngeal cancers. In order to be successful, a high vaccination coverage is needed. In Belgium, the vaccination was introduced in 2010 in the Flemish community and in 2011 in the French community. In the first vaccinated cohorts the coverage in Flemish and French Communities was respectively 84% (2010) and 29% (2012-2013). The latest data suggest that the Flemish Community (Flanders Region) attained a coverage of 91 % while the French Community (Walloon Region) attained a coverage of around 36 %. The regional difference in coverage offers a real-life case. The worst-case scenario could end up with proportionally one half of country having more HPV related cancers than the other half. Currently efforts are performed to increase the coverage rates in both regions and consequently decreasing this difference. Additionally, the updated recommendations regarding the HPV vaccination by the Belgian NITAG (National Immunization Technical Advisory Group) stated that the HPV vaccination should be gender neutral. This could stimulate the vaccination program and increase the coverage. The coverage rate in Flanders is among the highest in the world and the rate in the French Community is increasing. Efforts should be continued in order to maintain trust and increase the coverage rate. |
Author | Top, G Morales, I Brasseur, C Van Damme, P A Tjalma, Waa Ribesse, N |
Author_xml | – sequence: 1 givenname: Waa surname: Tjalma fullname: Tjalma, Waa organization: Multidisciplinary Breast cancer clinic, Gynaecological Oncology Unit, Department of Obstetrics & Gynaecology, Antwerp University Hospital, University of Antwerp, Wilrijkstraat 10, 2650 Antwerpen, Belgium – sequence: 2 givenname: C surname: Brasseur fullname: Brasseur, C organization: French Community, Immunization programme, Health department, Office of Birth and Childhood, Chaussée de Charleroi 95, B-1060 Bruxelles, Belgium – sequence: 3 givenname: G surname: Top fullname: Top, G organization: Infectious Disease Control and Vaccination, Flemish Agency for Care and Health, Ellipse Building, K. Albert II-laan 35, box 33, B-1030 Brussels, Belgium – sequence: 4 givenname: N surname: Ribesse fullname: Ribesse, N organization: French community, School Health Services support, Health department, Office of Birth and Childhood, Chaussée de Charleroi 95, B-1060 Bruxelles, Belgium – sequence: 5 givenname: I surname: Morales fullname: Morales, I organization: French Community, Immunization programme, Health department, Office of Birth and Childhood, Chaussée de Charleroi 95, B-1060 Bruxelles, Belgium – sequence: 6 givenname: P A surname: Van Damme fullname: Van Damme, P A organization: Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Campus 3 Eiken, Universiteitsplein, 1, 2610 Antwerpen, Belgium |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31110649$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkE9LxDAQxXNYcVfdryA5einkTzdpLoIu6goLelCPljSZdiNtUpt0wW9vxVV0LsPw5v3eMCdo5oOHGVowwllGclrM0TLGNzJVQSVbqWM055RSInK1QK-bxxe818Y4r5MLHpuwh0E3gJ3HaQe4BjvNLY5JJ8ChxtfQNm7s8OQJg3W-wSngAZrJHLH29svlBuy6Xpt0ho5q3UZYHvoper69eVpvsu3D3f36apv1VImUga0YZbYugMhKUsMNl1yIXGoqFGi-spwrrShUhBqVi6oquLRVQUEywQ3hp-jym9uPVQfWgE_T0WU_uE4PH2XQrvyveLcrm7AvxYoKWsgJcHEADOF9hJjKzkUDbas9hDGWjHFGVF5wNq2e_836Dfl5Kv8EgHp13w |
ContentType | Journal Article |
Copyright | Copyright © 2018 Facts, Views & Vision |
Copyright_xml | – notice: Copyright © 2018 Facts, Views & Vision |
DBID | NPM 7X8 5PM |
DatabaseName | PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 105 |
ExternalDocumentID | 31110649 |
Genre | Editorial Commentary |
GroupedDBID | ADBBV ADRAZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK EBS EJD HYE KQ8 M48 NPM OK1 PGMZT RPM 7X8 5PM |
ID | FETCH-LOGICAL-p196t-edb212df8e07b71c3c3736647a169ea35d339a91eb01c946bb837db81e7263c03 |
IEDL.DBID | RPM |
ISSN | 2032-0418 |
IngestDate | Tue Sep 17 21:24:55 EDT 2024 Fri Aug 16 04:19:29 EDT 2024 Sat Sep 28 08:32:43 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 2 |
Keywords | vaccination coverage Flanders Belgium difference Walloon Region cervical cancer HPV |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-p196t-edb212df8e07b71c3c3736647a169ea35d339a91eb01c946bb837db81e7263c03 |
Notes | SourceType-Other Sources-1 content type line 63 ObjectType-Editorial-2 ObjectType-Commentary-1 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516187/ |
PMID | 31110649 |
PQID | 2232094832 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6516187 proquest_miscellaneous_2232094832 pubmed_primary_31110649 |
PublicationCentury | 2000 |
PublicationDate | 2018-Jun 20180601 |
PublicationDateYYYYMMDD | 2018-06-01 |
PublicationDate_xml | – month: 06 year: 2018 text: 2018-Jun |
PublicationDecade | 2010 |
PublicationPlace | Belgium |
PublicationPlace_xml | – name: Belgium – name: Wetteren, Belgium |
PublicationTitle | Facts, views & vision in ObGyn |
PublicationTitleAlternate | Facts Views Vis Obgyn |
PublicationYear | 2018 |
Publisher | Universa Press |
Publisher_xml | – name: Universa Press |
SSID | ssj0000817259 |
Score | 2.1616843 |
Snippet | Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and... |
SourceID | pubmedcentral proquest pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 101 |
SubjectTerms | Opinion Paper |
Title | HPV vaccination coverage in the federal state of Belgium according to regions and their impact |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31110649 https://search.proquest.com/docview/2232094832 https://pubmed.ncbi.nlm.nih.gov/PMC6516187 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NT4MwFH_ZdjBejN_Or9TEKxtQaOGoi8tigtnBmZ0ktLRKssGizL_fRwGzGU_eIFBCXl_7fr--L4BbzrVUWriWYFpYnvZ9K9E8xatAuBq5mGuOBqInNpl5j3N_3gG_zYUxQftSZIN8sRzk2buJrVwt5bCNExtOoxHzqzLvfNiFLiroBkU322-ANtk0Sauag1u251Q9-SiuabS-fwLJ3_GQGwZmvA97DTIkd_UfHEBH5YewEzW-7yN4nUxfyFci8c5Ik8gq-hK3A5LlBGEc0VVdCPyCyREihSb3avGWrZcExyDFRBtFyoJUnRhQ00iSp8R4CUidKHkMs_HD82hiNd0RrBWumtJSqUCzk-pA2VxwR1JJOWXM44nDQpVQP6U0TEJHCduRoceEQC6aisBR3GVU2vQEenmRqzMgThAKhEVu6AmJfNINFVNaudILhWa-Svtw0wotRu2rXApJror1Z4zgwkWCiNtCH05rIcarukxG3Iq8D3xLvD8vVJWtt5_ghJsK180En_975AXsIrIJ6piuS-iVH2t1heihFNfQjbzg2ujMNw6nyaQ |
link.rule.ids | 230,315,730,783,787,888,2228,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLZgSMCF92M8g8S1W9u0SXuEiWk8hjiwiRNVkyYwsXUTdBz49bjpiraJC9xapamiOrY_119sgHPOtVRauJZgWlie9n0r1jzBq0C4GmMx1_waaN-zVse7efKfFsAvz8IY0r4UvVraH9TS3qvhVo4Gsl7yxOoP7Qbz8zLvvL4IS6ivtjcVpBsDHKBXNm3S8vbglu05eVc-ilqN_vdXKDnPiJxyMc116JaLK5glb7VxJmrya65u459XvwFrE9BJLorhTVhQ6RYstydp9W14bj10yWcs8c4Iisic2ImWhvRSggiR6LzkBL7BHD8iQ00uVf-lNx4QnIPRK7o_kg1J3uQBNzGJ04SYBAQpzmDuQKd59dhoWZPGC9YIFTKzVCLQoyU6UDYX3JFUUk4Z83jssFDF1E8oDePQUcJ2ZOgxITDMTUTgKO4yKm26C5V0mKp9IE4QCkRcbugJiaGqGyqmtHKlFwrNfJVU4ayURoQbO89WxKkajj8ixC0uxp5ocaqwV0gnGhUVOKJSllXgM3L7eSAvmj07gtIwxbMnX__g3zNPYaX12L6L7q7vbw9hFQFUUFDHjqCSvY_VMYKUTJyYLfkNst3qwg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB1BkRAX9qWsRuKaNokTOzlCoSpLUQ-AEAei2LGhok0rSDjw9UycBpWKE7dEsaNEz_a88TzPAJxwrqXSwrUE08LytO9bseYJXgXC1eiLuWZroHvLOvfe1aP_OFXqy4j2peg30sGwkfZfjbZyPJTNSifW7HVbzC_SvPPmONHNeVjAOWuzKUfdLMIBWmZTKq0oEW7ZnlNU5qM4s9EG_0knZ1WRU2amvQJP1QeW6pK3Rp6Jhvyayd34rz9YheUJ-SSnZZM1mFPpOix2J-H1DXju9B7IZyzxzgBGZCHwxBWH9FOCTJHoIvUEvsEcQyIjTc7U4KWfDwn2QS8WzSDJRqQo9oCDmcRpQkwggpRnMTfhvn1x1-pYkwIM1hgnZmapRKBlS3SgbC64I6mknDLm8dhhoYqpn1AaxqGjhO3I0GNCoLubiMBR3GVU2nQLaukoVTtAnCAUyLzc0BMSXVY3VExp5UovFJr5KqnDcYVIhAO8iFrEqRrlHxHyFxd9UFx56rBdIhSNy0wcUYVnHfgv7H4aFMmzfz9BREwS7QkCu__ueQSLvfN2dHN5e70HS8ijglJBtg-17D1XB8hVMnFoRuU3D3ftQg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HPV+vaccination+coverage+in+the+federal+state+of+Belgium+according+to+regions+and+their+impact&rft.jtitle=Facts%2C+views+%26+vision+in+ObGyn&rft.au=Tjalma%2C+WAA&rft.au=Brasseur%2C+C&rft.au=Top%2C+G&rft.au=Ribesse%2C+N&rft.date=2018-06-01&rft.pub=Universa+Press&rft.issn=2032-0418&rft.volume=10&rft.issue=2&rft.spage=101&rft.epage=105&rft_id=info%3Apmid%2F31110649&rft.externalDBID=PMC6516187 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2032-0418&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2032-0418&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2032-0418&client=summon |